证券代码：600750 证券简称：江中药业 公告编号：2023-031 江中药业股份有限公司（以下简称"公司"）董事会、监事会近日分别收到 公司董事何行真先生、监事会主席罗文华先生、监事曾庆梅女士的书面辞职报告。 因到龄退休，何行真先生申请辞去公司第九届董事会董事职务与公司董事会薪酬 与考核委员会委员职务，罗文华先生申请辞去公司监事会主席职务；因个人原因， 曾庆梅女士申请辞去公司监事职务。 根据《公司法》《公司章程》等相关规定，何行真先生的辞职不会导致公司 董事会成员低于法定最低人数，不会影响公司董事会的正常工作，辞职自辞职报 告送达公司董事会之日起生效。公司将按照法定程序尽快完成上述董事、董事会 薪酬与考核委员会委员的选举工作。截止公告日，何行真先生未持有本公司股票。 根据《公司法》及《公司章程》的相关规定，罗文华先生与曾庆梅女士的辞 职将导致公司监事人数低于法定最低人数，罗文华先生与曾庆梅女士的辞职报告 将于公司股东大会选举新任监事之日起生效，公司将按照相关规定完成监事会主 席和非职工代表监事的选举工作。在此之前，罗文华先生与曾庆梅女士将继续依 法履行其监事的职责。截止公告日，罗文华先生与曾庆梅女士未持有 ...

证券代码：600750 证券简称：江中药业 公告编号：2023-032 江中药业股份有限公司 关于雷贝拉唑钠肠溶片通过仿制药 一致性评价的公告 药品名称：雷贝拉唑钠肠溶片 剂型：片剂（肠溶片） 规格：20mg 注册分类：补充申请 申请人：晋城海斯制药有限公司 原批准文号：国药准字H20080125 审批结论：本品通过仿制药质量和疗效一致性评价 二、药品相关信息 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，江中药业股份有限公司(以下简称"公司")控股子公司晋城海斯制药 有限公司(以下简称"晋城海斯")收到国家药品监督管理局(以下简称"国家药 监局")核准签发的雷贝拉唑钠肠溶片(20mg)(以下简称"该药品")《药品补充 申请批准通知书》，批准该药品通过仿制药质量和疗效一致性评价。现将相关情 况公告如下： 一、该药品的基本情况 三、同类药品的市场状况 雷贝拉唑钠肠溶片最初由日本EISAI（卫材）公司首次研制成功，于1997年 首先在日本上市，随后分别在欧洲、美国、中国上市，其商品名称为波利特。经 查询，截止目前国内 ...

国浩律师（上海）事务所 法律意见书 关于江中药业股份有限公司 2023 年第一次临时股东大会的法律意见书 致：江中药业股份有限公司 江中药业股份有限公司（以下简称"公司"）2023 年第一次临时股东大会（以 下简称"本次股东大会"）现场会议定于 2023 年 9 月 8 日下午 14:30 在江西省南 昌市高新区火炬大道 788 号公司会议室召开，国浩律师（上海）事务所（以下简 称"本所"）接受公司的委托，指派本所律师出席会议，并依据《中华人民共和国 证券法》、《中华人民共和国公司法》、中国证券监督管理委员会《上市公司股 东大会规则》和《江中药业股份有限公司章程》（以下简称《公司章程》）出具 本法律意见书。 本所律师已经按照有关法律、法规的规定对本次股东大会召集、召开程序是 否合法及是否符合《公司章程》、股东大会召集人资格的合法有效性、出席会议 人员资格的合法有效性和股东大会表决程序、表决结果等发表法律意见。法律意 见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、法规的规定而出具。 本所律师同意将本 ...

(一) 股东大会召开的时间：2023 年 9 月 8 日 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 证券代码：600750 证券简称：江中药业 公告编号：2023-030 江中药业股份有限公司 (二) 股东大会召开的地点：江西省南昌市高新区火炬大街 788 号公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 27 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 302,865,287 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | 48.1162 | | 份总数的比例（%） | | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 会议由董事长刘为权先生主持，采取现场投票与网络投票相结合的表决方式。 表决方式符合《公司法》及《公司章程》的有关规定。 (五) 公 ...

江中药业股份有限公司 2023 年第一次临时股东大会会议材料 二〇二三年九月 江中药业股份有限公司 2023 年第一次临时股东大会会议材料 股票简称：江中药业 股票代码：600750 南 昌 江中药业股份有限公司 2023 年第一次临时股东大会会议材料 议案目录 2 江中药业股份有限公司 2023 年第一次临时股东大会会议材料 江中药业股份有限公司 股东大会会议须知 为了维护全体股东的合法权益、依法行使股东职权，确保股东大会的 正常秩序和议事效率，根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司股东大会规则》、《公司章程》及《公司股东大 会议事规则》，特制订本须知。 一、股东大会设秘书处，具体负责大会有关程序方面的事宜。 二、会议期间全体出席会议人员应以维护股东合法权益、确保大会正 常秩序、提高议事效率为原则，认真履行法定职责。 | | | 三、为保证股东大会的严肃性和正常秩序，除依法出席会议的公司股 东（或其授权代表）、董事、监事、董事会秘书、高级管理人员、聘请的 律师和董事会邀请参会的人员外，公司有权依法拒绝其他人士入场。 四、出席会议的股东（或其授权代表）必须在会议召开前十分钟向大 ...

Financial Performance - The company reported a half-year revenue of RMB 1.2 billion, representing a 15% increase compared to the same period last year[30]. - The net profit for the first half of 2023 was RMB 300 million, up 20% year-on-year[30]. - The company's operating revenue for the first half of 2023 reached ¥2,297,549,382.03, representing a 20.87% increase compared to the same period last year[52]. - Net profit attributable to shareholders of the listed company was ¥447,001,834.46, an increase of 13.95% year-on-year[52]. - The net profit after deducting non-recurring gains and losses was ¥414,012,620.10, reflecting a 16.04% increase compared to the previous year[52]. - The basic earnings per share for the first half of 2023 was ¥0.70, up 12.90% from ¥0.62 in the same period last year[52]. - The company achieved a net profit attributable to the parent company of 447 million yuan, an increase of 55 million yuan year-on-year, representing a growth of 13.95%[101]. - The company's operating revenue for the reporting period was 2.298 billion yuan, an increase of 397 million yuan year-on-year, with a growth rate of 20.87%[103]. - The revenue from the health and other businesses reached 285 million yuan, showing a significant year-on-year growth of 59.47%[106]. User Growth and Market Expansion - User data indicates a growth of 25% in active users, reaching 5 million by the end of June 2023[30]. - The company plans to launch two new products in Q3 2023, aiming to capture an additional 10% market share[30]. - The company is expanding its market presence in Southeast Asia, targeting a revenue contribution of 5% from this region by the end of 2024[30]. - A strategic acquisition of a local competitor is expected to be finalized by Q4 2023, which will enhance the company's product offerings[30]. - The management has indicated a positive outlook for future performance, supported by strategic initiatives and market expansion plans[57]. Research and Development - Research and development expenses increased by 30%, totaling RMB 150 million, reflecting the company's commitment to innovation[30]. - The company is committed to ongoing research and development in new products and technologies to enhance market competitiveness[57]. - The company's R&D intensity for 2022 was 3.89%, exceeding the required minimum of 2.96%[176]. Sustainability and Environmental Compliance - The management highlighted a focus on sustainability initiatives, aiming to reduce operational costs by 10% through energy efficiency measures[30]. - The company has implemented a comprehensive wastewater treatment process at the Luoting base, with a design capacity of 800 tons per day, utilizing biochemical treatment methods[168]. - The company’s wastewater treatment facilities are operating normally, with pollutant discharge concentrations meeting or exceeding national and local environmental protection standards[168]. - The company has established an online monitoring system for wastewater discharge, ensuring real-time tracking of key indicators such as COD, ammonia nitrogen, pH, flow rate, and water temperature[168]. - The company has made donations to strengthen the infrastructure of the local community, enhancing grassroots party organization cohesion[199]. - The company has supported local agricultural development by helping to sell over 500 pounds of blueberries from the village[200]. - The company has provided direct drinking water equipment to improve the living conditions in the village[200]. Financial Management and Assets - The company reported a significant improvement in cash flow, with a cash position of RMB 500 million, up 40% from the previous year[30]. - The company's cash and cash equivalents at the end of the period amounted to 2.627 billion yuan, an increase of 1.256 billion yuan, representing a growth of 91.59%[116]. - The company’s online business revenue accounted for over 10% of total sales during the reporting period[111]. - The company has established a mature channel coverage and terminal management capability, covering 200,000 terminal pharmacies and collaborating closely with 3,000 commercial partners[102]. Industry Trends and Challenges - The pharmaceutical industry is undergoing a restructuring due to the implementation of the eighth batch of national drug procurement and the unification of the national medical insurance catalog, leading to a more standardized and efficient use of medical insurance funds[59]. - The overall growth of the pharmaceutical manufacturing industry faced pressure, with the value added of the pharmaceutical manufacturing industry declining by 4.9% year-on-year in the first half of 2023[59]. - The company anticipates potential revenue impacts from the inclusion of its product in the national drug procurement list, which may affect future earnings[124]. - The company plans to expand its procurement channels for traditional Chinese medicine materials to ensure supply chain security amid price fluctuations[124]. Corporate Governance and Risk Management - The company did not face any significant risks that could materially affect its operations during the reporting period[44]. - The company will closely monitor national policies and industry trends to adjust its business strategies and enhance core competitiveness[124]. - The company has not faced any environmental pollution incidents or administrative penalties during the reporting period[177].

证券代码：600750 证券简称：江中药业 公告编号:2023-025 江中药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）将于 2023 年 8 月 24 日发布公 司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度 经营成果和财务状况，公司计划于 2023 年 8 月 29 日下午 15:00-16:30 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频结合网络互动召开，公司将针对 2023 年半年度经 营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许 的范围内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （网址：http://roadshow.sseinfo.com/） 会议召开时间：2023 年 8 月 29 日(星期二)下午 15:00-16:30 会议召开地点：上海证 ...

江中药业股份有限公司 关于参加沪市主板生物医药行业上市公司2022年年报 集体业绩说明会暨2023年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 江中药业股份有限公司（以下简称"公司"）已于2023年3月25日发布了公司 2022年年度报告，于2023年4月27日发布了公司2023年第一季度报告，为便于广大 投资者更全面深入地了解公司2022年度及2023年第一季度经营成果、财务状况，同 时更加充分地向投资者展示生物医药行业发展情况，公司计划于2023年5月12日下 午13:00-14:30参加沪市主板生物医药行业上市公司2022年年报集体业绩说明会，就 投资者关心的问题进行交流。 证券代码：600750 证券简称：江中药业 公告编号：2023-019 具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就投资者普遍 关注问题进行回答 。 二、说明会召开的时间、地点及活动日程 三、参加人员 董事长：刘为权先生 总经理：肖文斌先生 财务总监：李小俊先生 董事会秘书：田永静女 ...

Financial Position - The total assets of the company amount to 6,316,949,481.06 yuan, an increase from 6,243,659,088.84 yuan in the previous period[10]. - The company reported a total of 1,473,621,799.63 yuan in current liabilities, a decrease from 1,657,669,253.49 yuan in the previous period[10]. - The company has a total of 138.5 million yuan in other non-current financial assets[10]. - The total liabilities decreased to ¥1,561,109,382.72 from ¥1,748,281,711.63, indicating improved financial stability[50]. - Equity attributable to shareholders increased by 6.25% to ¥4,134,244,495.15 from ¥3,890,966,277.28[37]. Cash Flow - The company's cash and cash equivalents at the end of the period are 492,765,197.35 yuan, down from 550,324,166.65 yuan at the beginning of the period, resulting in a net decrease of 57,558,969.30 yuan[15]. - Operating cash inflow totaled $1,239,030,198.30, an increase from $751,780,919.26 in the previous period[71]. - Operating cash outflow amounted to $1,177,138,767.46, compared to $771,340,336.36 previously, resulting in a net cash flow from operating activities of $61,891,430.84, up from a negative $19,559,417.10[71]. - Investment cash inflow was $763,779,065.02, down from $864,376,241.00 in the prior period[71]. - Investment cash outflow reached $883,229,465.16, compared to $679,966,641.72 previously, leading to a net cash flow from investing activities of -$119,450,400.14, down from $184,409,599.28[71]. - The company received tax refunds amounting to $21,567,303.42[71]. - Cash received from other operating activities was $39,269,633.66, compared to $19,211,152.76 previously[71]. - Total cash paid for taxes was $157,140,068.85, up from $74,980,014.68[71]. Revenue and Profitability - The company's operating revenue for Q1 2023 reached ¥1,316,378,726.66, representing a year-on-year increase of 41.44%[20]. - The net profit attributable to shareholders of the listed company was ¥240,831,060.77, up 31.10% compared to the same period last year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥224,783,546.46, reflecting a 29.61% increase year-on-year[20]. - The basic earnings per share for the period was ¥0.38, which is a 31.03% increase from the previous year[20]. - The gross profit margin for over-the-counter drugs was 72.80%, an increase of 3.41 percentage points compared to the same period last year[24]. - The revenue from the health products and others segment surged by 184.66% year-on-year, although the gross profit margin decreased to 33.15%[24]. - Revenue from the East China region increased by 83.65% year-on-year, amounting to ¥459,336,359.19[24]. - The gross margin for the pharmaceutical industry was 67.97%, a decrease of 0.99 percentage points year-on-year[37]. - The company reported a decrease in the gross margin for health products and others, primarily due to changes in product revenue structure[39]. Expenses and Investments - The company's total operating costs for Q1 2023 were CNY 1,034,301,889.35, compared to CNY 721,704,291.98 in Q1 2022, marking an increase of around 43.4%[70]. - Research and development expenses for Q1 2023 amounted to CNY 26,642,289.45, slightly down from CNY 27,972,879.52 in Q1 2022[70]. - The company's sales expenses for Q1 2023 were CNY 531,495,354.11, up from CNY 353,212,883.66 in Q1 2022, indicating an increase of approximately 50.6%[70]. - The tax expenses for Q1 2023 were CNY 46,598,116.68, compared to CNY 36,263,791.67 in Q1 2022, reflecting an increase of about 28.6%[70]. - The investment income for Q1 2023 showed a loss of CNY 350,858.42, compared to a gain of CNY 1,189,302.97 in Q1 2022[70]. Legal and Other Matters - As of the reporting period, the company has a remaining overdue principal of 6.75 million yuan from entrusted loans to Changrong Automobile, with legal actions ongoing[4]. - The company has initiated a lawsuit against Changrong Automobile and related guarantors to recover overdue loans[4]. - The company has plans for future entrusted financial management, indicating ongoing investment strategies[5]. - The company has a total of 3,100,000 shares held through margin accounts by its representative, Luo Jun[3]. - The total number of ordinary shareholders at the end of the reporting period was 35,551[27].

Financial Performance - The company's operating revenue for 2022 was CNY 3,811,641,510.59, representing a 32.63% increase compared to CNY 2,873,974,462.18 in 2021[9] - The net profit attributable to shareholders for 2022 was CNY 596,058,708.67, up 17.87% from CNY 505,687,248.49 in the previous year[9] - The net profit after deducting non-recurring gains and losses was CNY 506,520,866.82, reflecting a 19.42% increase from CNY 424,156,470.17 in 2021[9] - The net cash flow from operating activities for 2022 was CNY 1,015,989,416.27, a 10.79% increase compared to CNY 917,037,660.75 in 2021[9] - The company's total assets at the end of 2022 were CNY 6,243,659,088.84, which is a 4.10% increase from CNY 5,997,600,248.38 at the end of 2021[9] - The basic earnings per share for 2022 was CNY 0.94, representing a 17.50% increase compared to CNY 0.80 in 2021[37] - The diluted earnings per share for 2022 was also CNY 0.94, consistent with the basic earnings per share[37] - The gross profit margin for the main business was 64.93%, an increase of 0.52 percentage points compared to the same period last year[78] Dividends and Shareholder Returns - The proposed cash dividend for 2022 is CNY 6.5 per 10 shares, which would total approximately CNY 40,920.68 million, accounting for 68.65% of the net profit attributable to shareholders[15] - The total cash dividend for 2022, including the distribution from the first three quarters, is estimated to be CNY 72,399.78 million, exceeding 121.46% of the net profit attributable to shareholders[15] - The company maintained a cumulative cash dividend ratio of 50% of the net profit attributable to the parent company since its restructuring listing, emphasizing shareholder returns[62] Operational Highlights - The company completed a share buyback of 33,000 restricted shares in February 2023, which will affect the total number of shares for the dividend distribution[15] - There were no significant risks identified that could materially impact the company's operations during the reporting period[19] - The company achieved operating revenue of 3.812 billion yuan in 2022, a year-on-year increase of 32.63%[45] - The company’s total share capital decreased from 630,000,000 shares at the beginning of the year to 629,581,958 shares at the end of the year due to the cancellation of treasury shares[37] Segment Performance - The non-prescription drug segment generated revenue of 2.618 billion yuan, up 21.31% year-on-year, with core products showing significant growth[52] - The health business reported revenue of 409 million yuan, marking a substantial increase of 66.99% year-on-year[50] - The prescription drug segment saw revenue of 745 million yuan, a remarkable growth of 64.40% year-on-year, largely due to the integration of Haise Pharmaceutical[55] Research and Development - The company introduced 1 generic drug and received 4 supplementary approvals for existing products during the reporting period[56] - The company increased R&D investment and completed 2 special medical products on-site verification during the reporting period[136] - The company’s R&D expenses amounted to CNY 99.97 million, reflecting a year-on-year increase of 13.83%[75] - The company employed 239 R&D personnel, making up 5.9% of the total workforce[102] Market Trends and Challenges - The company anticipates challenges from global economic downturns and ongoing price reductions in generic drugs, necessitating operational innovations[113] - The OTC market is experiencing increased demand due to a shift towards preventive healthcare, with a growing focus on immune enhancement products[114] - The health products market is entering a "golden period" of rapid growth, driven by rising consumer awareness and demand for self-care[117] - The traditional Chinese medicine market is expected to benefit from supportive policies, with a focus on high-quality development and innovation[114] Environmental and Social Responsibility - The group has implemented a wastewater treatment facility with a capacity of 20,000 m³/h, ensuring compliance with discharge standards[166] - The group has adopted natural gas as a clean energy source across all production bases, with emissions of SO2 and nitrogen oxides meeting standards[167] - Jiangzhong Pharmaceutical invested CNY 2.0808 million in social assistance projects, including CNY 1.45 million in funds and CNY 630,800 in material donations[174] - The company has committed to maintaining operational independence and protecting the rights of shareholders, ensuring no misuse of its controlling position[177] Strategic Initiatives - The company is expected to officially launch a new "smart, green, and economical" manufacturing park by the end of 2023[59] - The company has established a robust organizational structure to support its "14th Five-Year Plan" strategy, focusing on talent development and effective execution[61] - The company is actively enhancing its investor relations management tools and improving ESG information disclosure to create a more transparent corporate image[62]